Polyrizon Ltd. (PLRZ)
Automate Your Wheel Strategy on PLRZ
With Tiblio's Option Bot, you can configure your own wheel strategy including PLRZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PLRZ
- Rev/Share 0.0
- Book/Share 1.2602
- PB 0.5594
- Debt/Equity 0.0
- CurrentRatio 10.1648
- ROIC -0.2463
- MktCap 3756474.0
- FreeCF/Share -0.2735
- PFCF -3.275
- PE -1.914
- Debt/Assets 0.0
- DivYield 0
- ROE -0.561
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Company demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models Raanana, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced compelling results from recent ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform.
Read More
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
Published: April 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Raanana, Israel, April 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized branding and trademark consultancy firm, renowned for working with leading pharmaceutical and medical device companies worldwide.
Read More
Polyrizon Ltd. Announces $17.0 Million Private Placement
Published: March 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
RAANANA, ISRAEL, March 31, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $17.0 million of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit.
Read More
About Polyrizon Ltd. (PLRZ)
- IPO Date 2024-10-29
- Website https://www.polyrizon-biotech.com
- Industry Biotechnology
- CEO Tomer Izraeli
- Employees 2